<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Miracor Medical SA 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=41306></link><description><![CDATA[Miracor Medical SA 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 22:38:00 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2022/08/12_31017998_20220823162938_5114264369.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Miracor Medical Announces FDA IDE Approval For PiCSO® Pivotal Study]]></title><link>https://www.newswire.co.kr/newsRead.php?no=949947</link><description><![CDATA[AWANS, Belgium--(Business Wire/Korea Newswire)--Miracor Medical SA (Miracor Medical) has announced the approval of an Investigational Device Exemption (IDE) from the FDA, enabling the company to initiate a pivotal study with its Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) technology. The PiCSO-AMI-II multicenter, randomized trial will enroll 300 patients with anterior ST...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2022/08/31017998_20220823163226_7218955466.jpg]]></url></image><pubDate>Tue, 23 Aug 2022 17:00:00 +0900</pubDate></item></channel></rss>